Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1634/theoncologist.2017-0152 http://scihub22266oqcxt.onion/10.1634/theoncologist.2017-0152 C5507655!5507655!28576856     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Oncologist 2017 ; 22 (7): 762-7 Nephropedia Template TP {{tp|p=28576856|t=2017. Oncology Drug Approvals: Evaluating Endpoints and Evidence in an Era of Breakthrough Therapies |pdf=|usr=}}{{28576856}} gab.com Text Oncology Drug Approvals: Evaluating Endpoints and Evidence in an Era of Breakthrough Therapies JO: Oncologist http://www.kidney.de/pget.php?&tw=1&pmid=28576856 #FOAvip With the Breakthrough Therapy Designation program adding to the tools that the U.S. Food and Drug Administration (FDA) has for expediting drug development, the FDA reassessed the endpoints needed for approval of transformative therapies. Although the demonstration of an improvement in overall survival remains the gold standard for drug approval, innovation in cancer research has led to use of other endpoints in regulatory decision?making. These endpoints include substantially delaying tumor progression or extending progression?free survival, substantially reducing tumor size for a prolonged time, improving objective response rate and duration of response, or improving cancer?related symptoms and patient function. Twit Text FOAVip Oncology Drug Approvals: Evaluating Endpoints and Evidence in an Era of Breakthrough Therapies ????Oncologist http://www.kidney.de/pget.php?&tw=1&pmid=28576856 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28576856 #FOAvip English Wikipedia <ref>{{Cite pmid|28576856}}</ref> Oncology Drug Approvals: Evaluating Endpoints and Evidence in an Era of Breakthrough Therapies #MMPMID28576856 Blumenthal GM; Kluetz PG; Schneider J; Goldberg KB; McKee AE; Pazdur R Oncologist 2017[Jul]; 22 (7): 762-7 PMID28576856show ga With the Breakthrough Therapy Designation program adding to the tools that the U.S. Food and Drug Administration (FDA) has for expediting drug development, the FDA reassessed the endpoints needed for approval of transformative therapies. Although the demonstration of an improvement in overall survival remains the gold standard for drug approval, innovation in cancer research has led to use of other endpoints in regulatory decision?making. These endpoints include substantially delaying tumor progression or extending progression?free survival, substantially reducing tumor size for a prolonged time, improving objective response rate and duration of response, or improving cancer?related symptoms and patient function. äOncology Drug Approvals: Evaluating Endpoints and Evidence in an Era o(epmc).pdf DeepDyve Pubget Overpricing